Clear benefit for patients with synovial sarcoma demonstrated in updated data from ongoing phase 1 trial with adp-a2m4 presented at esmo

- clinical responses in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out 12 patients - - clinical responses in 7 out of 12 patients with synovial sarcoma, and clinical benefit in 11 out 12 patients -
ADP Ratings Summary
ADP Quant Ranking